The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The expanding treatment options for R/R follicular lymphoma
Mitchell Smith, MD, PhD, CMO of the Follicular Lymphoma Foundation, London, UK, discusses the expanding treatment options for relapsed/refractory (R/R) follicular lymphoma, including new bispecific antibodies, CAR T-cell therapies, and small molecules. Dr Smith highlights the need for shared decision making between patients and healthcare professionals, requiring education and consideration of individual patient circumstances. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
